Toxicity parameters for solid and “liquid” tumor models treated with metronomic CTX, Vbl, Nvb, or CDDP
Tumor model (description), drug, and drug dose, mg/kg . | Total WBC count, per μL PB . | Neutrophil counts, per 104 PB cells . | Lymphocyte counts, per 104 PB cells . | Bone marrow proliferation, cpm/105 cells . | Body weight, g . |
|---|---|---|---|---|---|
| MeWo (human melanoma), CTX | |||||
| 0 | 4.06 ± 2.38 | 7.41 ± 4.13 | 11.29 ± 11.34 | 9563 ± 3045 | 24.46 ± 1.20 |
| 10 | 2.62 ± 0.65 | 7.23 ± 3.79 | 13.01 ± 5.70 | 12460 ± 3079 | 26.67 ± 0.94 |
| 20 | 1.24 ± 0.63 | 6.69 ± 3.20 | 5.99 ± 2.00 | 10776 ± 1949 | 25.85 ± 1.91 |
| 40 | 1.02 ± 0.22 | 4.02 ± 1.78 | 6.93 ± 3.36 | 8844 ± 372 | 24.09 ± 2.56 |
| 50 | 0.76 ± 0.42 | 2.00 ± 1.38* | 6.17 ± 4.52 | 6359 ± 1908 | 22.61 ± 1.03 |
| MDA-MB-231/MVB9 (human breast cancer, resistant to Vbl), Vbl | |||||
| 0.00 | 2.30 ± 0.44 | 8.57 ± 4.84 | 3.15 ± 1.72 | 7848 ± 1956 | 19.74 ± 1.13 |
| 0.16 | 2.28 ± 0.42 | 8.57 ± 3.68 | 3.01 ± 1.25 | 8920 ± 766 | 19.39 ± 1.67 |
| 0.33 | 1.48 ± 0.55 | 5.51 ± 2.24 | 2.56 ± 1.02 | 6422 ± 1934 | 19.22 ± 0.85 |
| 0.67 | 0.86 ± 0.27 | 6.46 ± 2.90 | 1.89 ± 2.02 | 9594 ± 1400 | 19.03 ± 1.50 |
| MDA-MB-231/LM2-4 (metastatic variant), Nvb | |||||
| 0 | 2.10 ± 0.54 | 18.20 ± 4.40 | 3.44 ± 2.68 | 6988 ± 2295 | 20.80 ± 0.95 |
| 3 | 1.88 ± 0.76 | 13.53 ± 2.72 | 2.11 ± 0.97 | 8844 ± 1135 | 22.15 ± 0.62 |
| 6 | 1.88 ± 0.48 | 9.15 ± 4.42* | 4.76 ± 3.12 | 4986 ± 3870 | 22.40 ± 1.76 |
| 9 | 1.20 ± 0.62 | 6.24 ± 2.31† | 2.25 ± 1.01 | 4301 ± 1068 | 21.10 ± 1.16 |
| 12 | 1.18 ± 0.30 | 3.94 ± 1.68† | 1.98 ± 1.02 | 3317 ± 761* | 19.70 ± 1.78 |
| Friend erythroleukemia, CTX | |||||
| 0 | 3.33 ± 0.35 | 5.98 ± 1.38 | 6.30 ± 1.83 | 4209 ± 1282 | 20.18 ± 1.25 |
| 10 | 2.96 ± 0.96 | 6.81 ± 1.20 | 6.80 ± 0.87 | 3345 ± 1035 | 19.05 ± 3.06 |
| 20 | 2.38 ± 0.77 | 5.70 ± 2.30 | 7.31 ± 2.73 | 3346 ± 1644 | 19.82 ± 0.75 |
| 50 | 1.65 ± 0.68 | 3.72 ± 1.81 | 5.07 ± 1.85 | 3150 ± 897 | 16.38 ± 2.27† |
| Friend erythroleukemia, CDDP | |||||
| 0.0 | 4.50 ± 1.02 | 9.42 ± 5.09 | 11.58 ± 1.90 | 3464 ± 1504 | 16.6 ± 0.37 |
| 0.5 | 3.74 ± 0.40 | 10.90 ± 10.56 | 9.66 ± 5.87 | 4108 ± 1503 | 16.9 ± 0.90 |
| 1.0 | 3.73 ± 1.41 | 7.67 ± 4.00 | 9.84 ± 3.66 | 6295 ± 1288 | 16.4 ± 1.04 |
| 2.0 | 3.88 ± 0.63 | 4.22 ± 1.27 | 8.10 ± 3.42 | 2794 ± 988 | 15.0 ± 0.89* |
| 3.0 | 3.32 ± 1.30 | 6.17 ± 3.57 | 8.15 ± 3.24 | 3684 ± 1101 | 13.9 ± 1.50* |
Tumor model (description), drug, and drug dose, mg/kg . | Total WBC count, per μL PB . | Neutrophil counts, per 104 PB cells . | Lymphocyte counts, per 104 PB cells . | Bone marrow proliferation, cpm/105 cells . | Body weight, g . |
|---|---|---|---|---|---|
| MeWo (human melanoma), CTX | |||||
| 0 | 4.06 ± 2.38 | 7.41 ± 4.13 | 11.29 ± 11.34 | 9563 ± 3045 | 24.46 ± 1.20 |
| 10 | 2.62 ± 0.65 | 7.23 ± 3.79 | 13.01 ± 5.70 | 12460 ± 3079 | 26.67 ± 0.94 |
| 20 | 1.24 ± 0.63 | 6.69 ± 3.20 | 5.99 ± 2.00 | 10776 ± 1949 | 25.85 ± 1.91 |
| 40 | 1.02 ± 0.22 | 4.02 ± 1.78 | 6.93 ± 3.36 | 8844 ± 372 | 24.09 ± 2.56 |
| 50 | 0.76 ± 0.42 | 2.00 ± 1.38* | 6.17 ± 4.52 | 6359 ± 1908 | 22.61 ± 1.03 |
| MDA-MB-231/MVB9 (human breast cancer, resistant to Vbl), Vbl | |||||
| 0.00 | 2.30 ± 0.44 | 8.57 ± 4.84 | 3.15 ± 1.72 | 7848 ± 1956 | 19.74 ± 1.13 |
| 0.16 | 2.28 ± 0.42 | 8.57 ± 3.68 | 3.01 ± 1.25 | 8920 ± 766 | 19.39 ± 1.67 |
| 0.33 | 1.48 ± 0.55 | 5.51 ± 2.24 | 2.56 ± 1.02 | 6422 ± 1934 | 19.22 ± 0.85 |
| 0.67 | 0.86 ± 0.27 | 6.46 ± 2.90 | 1.89 ± 2.02 | 9594 ± 1400 | 19.03 ± 1.50 |
| MDA-MB-231/LM2-4 (metastatic variant), Nvb | |||||
| 0 | 2.10 ± 0.54 | 18.20 ± 4.40 | 3.44 ± 2.68 | 6988 ± 2295 | 20.80 ± 0.95 |
| 3 | 1.88 ± 0.76 | 13.53 ± 2.72 | 2.11 ± 0.97 | 8844 ± 1135 | 22.15 ± 0.62 |
| 6 | 1.88 ± 0.48 | 9.15 ± 4.42* | 4.76 ± 3.12 | 4986 ± 3870 | 22.40 ± 1.76 |
| 9 | 1.20 ± 0.62 | 6.24 ± 2.31† | 2.25 ± 1.01 | 4301 ± 1068 | 21.10 ± 1.16 |
| 12 | 1.18 ± 0.30 | 3.94 ± 1.68† | 1.98 ± 1.02 | 3317 ± 761* | 19.70 ± 1.78 |
| Friend erythroleukemia, CTX | |||||
| 0 | 3.33 ± 0.35 | 5.98 ± 1.38 | 6.30 ± 1.83 | 4209 ± 1282 | 20.18 ± 1.25 |
| 10 | 2.96 ± 0.96 | 6.81 ± 1.20 | 6.80 ± 0.87 | 3345 ± 1035 | 19.05 ± 3.06 |
| 20 | 2.38 ± 0.77 | 5.70 ± 2.30 | 7.31 ± 2.73 | 3346 ± 1644 | 19.82 ± 0.75 |
| 50 | 1.65 ± 0.68 | 3.72 ± 1.81 | 5.07 ± 1.85 | 3150 ± 897 | 16.38 ± 2.27† |
| Friend erythroleukemia, CDDP | |||||
| 0.0 | 4.50 ± 1.02 | 9.42 ± 5.09 | 11.58 ± 1.90 | 3464 ± 1504 | 16.6 ± 0.37 |
| 0.5 | 3.74 ± 0.40 | 10.90 ± 10.56 | 9.66 ± 5.87 | 4108 ± 1503 | 16.9 ± 0.90 |
| 1.0 | 3.73 ± 1.41 | 7.67 ± 4.00 | 9.84 ± 3.66 | 6295 ± 1288 | 16.4 ± 1.04 |
| 2.0 | 3.88 ± 0.63 | 4.22 ± 1.27 | 8.10 ± 3.42 | 2794 ± 988 | 15.0 ± 0.89* |
| 3.0 | 3.32 ± 1.30 | 6.17 ± 3.57 | 8.15 ± 3.24 | 3684 ± 1101 | 13.9 ± 1.50* |
Solid and erythroleukemia tumor models were treated with CTX administered through the drinking water on a daily basis, Vlb by intraperitoneal injection 3 times a week, Nvb by oral gavage 3 times a week, and CDDP by intraperitoneal injection twice a week at the indicated doses. Measurements (values are present as mean ± SD) of total WBC, neutrophil, and lymphocyte counts and bone marrow proliferation were performed 1 week after the initiation of treatment, as described in “Study design.” Body weights of all animals were monitored on a weekly basis. Body weight represents mean ± SD after 3 weeks of treatment.
Significant differences from control for .05 > P > .01.
Significant differences from control are indicated for P < .01.